Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine metabolic disorder of reproductive age women, often accompanied by obesity, hyperandrogenism, hyperinsulinemia, insulin resistance (IR), and other metabolic syndrome (MS). Oxidative stress (OS) is considered as a potential inducing factor in the pathogenesis of PCOS at present. Glucagon-like peptide-1 (glp-1) receptor agonist and analogues as new therapeutic agents in the treatment of type 2 diabetes mellitus (T2DM), can lose weight, improve IR, resist OS and reduce the expression of inflammatory cytokines, thus they have been widely used in the clinical application of patients with PCOS. The author reviews the latest advances of glucagon-like peptide-1 on polycystic ovary syndrome. Key words: Receptors, glucagon/AG/TU; Glucagon-like peptide 1/PD; Polycystic ovary syndrome/DT; Review

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.